316 Results for "

Integrin beta

" in MedChemExpress (MCE) Product Catalog:
Products (316)

316 Results for "Integrin beta" in MCE Product Catalog:

74
74 Publications Verification
Cat. No.: HY-16143
CAS No.: 199807-35-7
Synonyms: EMD 121974 TFA
Target:  

Integrin Autophagy

Research Areas:  

Cancer

Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively.
loading...
    loading...
74
74 Publications Verification
Cat. No.: HY-16141
CAS No.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-P0023
CAS No.: 161552-03-0
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-P0023A
CAS No.: 500577-51-5
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-100506
CAS No.: 1320346-97-1
Purity:  99.43%
Target:  

Integrin

Research Areas:  

Cancer

GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-18676
CAS No.: 2070015-22-2
Research Areas:  

Cancer

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain) . OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner . OSU-T315 causes cell death through apoptosis and autophagy .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-13535
CAS No.: 262438-43-7
Target:  

Integrin

Research Areas:  

Cancer

ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-13535A
CAS No.: 904763-27-5
Purity:  99.04%
Synonyms: ATN-161 TFA salt
Target:  

Integrin

Research Areas:  

Cancer

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-18644
CAS No.: 1564286-55-0
Target:  

Integrin

Research Areas:  

Cancer

CWHM-12 is a potent inhibitor of αV integrins with IC50s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1740
CAS No.: 114681-65-1
Target:  

Integrin Apoptosis Caspase

Research Areas:  

Inflammation/Immunology

RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1740A
Target:  

Integrin Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100445A
Purity:  98.28%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100445
CAS No.: 1689540-62-2
Purity:  99.51%
Target:  

Integrin

Research Areas:  

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15102
CAS No.: 227963-15-7
Purity:  99.50%
Synonyms: L-000845704
Target:  

Integrin

Research Areas:  

Inflammation/Immunology Cancer

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13306
CAS No.: 1228445-38-2
Purity:  99.71%
Target:  

Integrin

Research Areas:  

Metabolic Disease

Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14951
CAS No.: 402567-16-2
Purity:  99.75%
Synonyms: SB 683699
Target:  

Integrin

Research Areas:  

Neurological Disease

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15770
CAS No.: 232271-19-1
Purity:  98.06%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

TR-14035 is a orally active dual α4β74β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100563
CAS No.: 250612-42-1
Purity:  99.92%
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100563A
CAS No.: 217099-14-4
Purity:  99.83%
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408
CAS No.: 404882-00-4
Target:  

Integrin VEGFR

Research Areas:  

Cancer

Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
loading...
    loading...